Phase two required us to scale up fusion. We knew we could access markets that were probably ten times larger than the testing markets if we could reduce the cost of fusion. But we had to reduce it by like a thousand times. We did that through clever use of what we call gas targetry and neutron multiplication. That allowed us to produce enough neutrons from a fusion process that would allow us to change materials.
So this is a process nuclear engineers called transmutation where if you hit an element or an isotope with a neutron, it actually becomes a different element or isotope. And these materials have a use. And that's why they're so valuable primarily in medicine at small-scale. One of the reactions we cause we use neutrons for is to turn uranium that we can buy for like $6 a gram into a medicine called molybdenum-99.
And molybdenum-99 is worth like $150 million dollars a gram. Right. So lutetium-177 is an isotope we produce for cancer therapy, which is worth like 1 to $2 billion dollars per gram. That's phase two is actually like using the neutrons from fusion to drive the isotope production process.
